After saying earlier this year that it would start deprioritizing its research into women’s health drugs, Bayer still appears willing to spend some money on developing its birth control implant portfolio.

拜耳公司在今年早些时候表示，将开始对女性保健药物的研究进行非优先化，但似乎仍愿意投入一些资金来开发其避孕植入产品组合。

The German pharmaceutical giant has inked a deal with CrossBay Medical, the makers of a device to help clinicians gain access to the uterus with considerably less pain compared to traditional methods.

这家德国制药巨头已与CrossBay Medical达成协议，CrossBay Medical是一种帮助临床医生进入子宫的设备制造商，与传统方法相比，其疼痛程度要低得多。

Bayer said it believes the company’s low-friction CrossGlide technology could be adapted to help place its various intrauterine devices, or IUDs—including its Mirena, Kyleena and Skyla contraceptives, which slowly release the hormone levonorgestrel over a span of years.

拜耳公司表示，它相信该公司的低摩擦CrossGlide技术可以用于放置各种宫内节育器，包括其曼月乐、凯莉娜和Skyla避孕药，这些避孕药在数年内缓慢释放激素左炔诺孕酮。

CrossBay’s approach does away with the metal forceps and grasping of tissue that are typically needed to reach the inner uterus during a transvaginal procedure. The company’s CrossGlide platform instead relies on a flexible catheter that gently follows the natural curves of the cervical canal.

CrossBay的方法消除了在经阴道手术中通常需要到达子宫内膜的金属钳和组织的抓取。相反，该公司的CrossGlide平台依赖于一种柔性导管，该导管轻轻地遵循宫颈管的自然曲线。

Its devices have previously been cleared by the FDA for use in gynecological exams such as endometrial biopsies, as well as for in vitro fertilization and embryo transfers. CrossBay has also worked with Hologic (PDF) to help develop its Definity cervical dilator.

其设备之前已被FDA批准用于妇科检查，如子宫内膜活检，以及体外受精和胚胎移植。CrossBay还与Hologic（PDF）合作，帮助开发其Definity宫颈扩张器。

Bayer’s deal aims to use CrossGlide to produce a new type of single-handed IUD inserter device, and includes an option to license the technology. The financial terms of the agreement were not disclosed.

拜耳的交易旨在使用CrossGlide生产一种新型的单手宫内节育器插入器装置，并包括该技术的许可选择。协议的财务条款没有披露。

The partnership will also “result in adapting the manufacturing process and industrialization of the CrossGlide technology, building on Bayer’s expertise in the field specifically at the company’s state-of-the art production site in Turku, Finland,” the companies said in their announcement.

两家公司在公告中表示，该合作关系还将“以拜耳在该领域的专业知识为基础，特别是在该公司位于芬兰图尔库的最先进生产基地，调整CrossGlide技术的制造工艺和产业化”。

“We invented CrossGlide to help improve the insertion experience by creating a flexible system that follows the shape of a woman’s cervix. By doing this, we created a new paradigm for office-based procedures for both women and healthcare providers,” said CrossBay founder and CEO Piush Vidyarthi.

CrossBay创始人兼首席执行官Piush Vidyarthi说：“我们发明了CrossGlide，通过创建一个遵循女性子宫颈形状的灵活系统来帮助改善插入体验。通过这样做，我们为女性和医疗保健提供者创建了一个基于办公室的程序的新范例。”。

“We are partnering with Bayer as a market leader in intrauterine contraception as we believe more women will be better served using the CrossGlide technology and therefore provided one of the most effective birth control options for consideration,” Vidyarthi said.

维迪亚西说：“我们正在与拜耳合作，成为宫内节育领域的市场领导者，因为我们相信使用CrossGlide技术可以更好地为更多女性提供服务，因此可以考虑提供最有效的节育选择之一。”。

This past March, Bayer said that it would no longer maintain its long-term, specialized focus on developing women’s health medication, instead directing its pharma R&D attention to core areas in cancer, cardiovascular disease, neurology, immunology and rare diseases.

今年3月，拜耳表示，它将不再长期专注于开发女性健康药物，而是将其药物研发注意力转向癌症、心血管疾病、神经病学、免疫学和罕见病等核心领域。

However, the company did admit that it would continue work on developing the nonhormonal drug elinzanetant, currently in phase three trials for treating the vasomotor symptoms of menopause—a condition more commonly known as hot flashes—with a market that Bayer has predicted could bring blockbuster sales topping 1 billion euros..

然而，该公司确实承认，它将继续开发非激素药物elinzanetant，目前正在进行治疗更年期血管舒缩症状的三期临床试验，更年期血管舒缩症状更常见的是潮热，拜耳预测该市场可能会带来突破10亿欧元的轰动销售额。。